

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 April 2002 (25.04.2002)

PCT

(10) International Publication Number
WO 02/33413 A1

(51) International Patent Classification⁷: **G01N 33/558**,
33/569, 33/571

(21) International Application Number: PCT/GB01/04589

(22) International Filing Date: 15 October 2001 (15.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0025245.2 14 October 2000 (14.10.2000) GB

(71) Applicant and

(72) Inventor: **LEE, Helen** [FR/GB]; University of Cambridge, Department of Haematology, East Anglia Blood Centre Site, Long Road, Cambridge CB2 2PT (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **DINEVA, Magda, Anastassova** [BG/GB]; 62 Greystoke Road, Cambridge CB1 8DS (GB).

(74) Agent: **DAVIES, Jonathan, Mark**; Reddie & Grose, 16 Theobalds Road, London WC1X 8PL (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DIPSTICK ASSAY

(57) **Abstract:** The invention provides a dipstick and a kit comprising the dipstick, for testing for the presence of a plurality of different targets in a sample solution which comprises: a dipstick having a plurality of different capture zones and, immobilised to each capture zone, a different capture moiety, each capture moiety capable of capturing a different target; and, separately, a plurality of different detection probes, each detection probe capable of binding to a different target and each detection probe being labelled with or enabling the formation of a detection signal so that the presence of each target is indicated by the formation of a signal at the capture zone for that target; wherein the target for at least two of the capture moieties is a disease causing micro-organism or a marker indicating the existence of a disease, disorder, or condition of the host from which the sample solution was derived, and wherein at least two of the capture moieties are capable of binding to different components or markers of the same disease causing micro-organism as targets for those capture moieties. The dipsticks and kits may be used for confirmatory assays of infection by an infectious agent or disease causing microorganisms.

WO 02/33413 A1



- 1 -

DIPSTICK ASSAY

Confirmatory Dipstick Assay

The present invention relates to dipsticks, kits comprising dipsticks, and to dipstick assays for confirming infection
5 by an infectious agent or disease causing microorganism, or for the presence of a disease, disorder or condition not caused by an infectious agent or disease causing microorganism.

After a person has been identified in a general screening
10 procedure as potentially infected with an infectious agent it is often necessary to confirm that this diagnosis is correct. This is particularly the case for diagnosis of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) infection. An immunoblot assay is typically performed to
15 confirm whether or not the result obtained in the general screening procedure is correct.

However, immunoblot assays have several disadvantages. These assays comprise multiple steps, requiring stepwise addition of different components in a particular order. Incubation
20 and washing steps are necessary after addition of each new component. It may not be possible to complete an assay in less than 5 hours and usually more than 20 hours is required. This is a significant disadvantage because it is desirable to obtain the result as quickly as possible, for
25 example to keep patient waiting times to a minimum. In remote areas, if the general screening and confirmatory assays are not performed during a single visit from a patient, the patient may never obtain the test result because they may be unlikely or unable to return at a later
30 date.

- 2 -

A further disadvantage of immunoblot assays is that specialist equipment is required. Such equipment may not be readily available, particularly in remote areas or resource-poor countries, thus requiring the patient to travel long distances for the tests to be performed. The relatively high cost of immunoblot assays can also reduce their availability in resource-poor countries. Patient and public health can be endangered if tests are not readily available, or if results are not communicated to patients because they are unlikely or unable to return at a later date.

It is desired to provide confirmatory assays which are quick and easy to perform, and which do not require use of specialist equipment.

According to a first aspect of the invention there is provided a kit for testing for the presence of a plurality of different targets in a sample solution which comprises: a dipstick having a plurality of different capture zones and, immobilised to each capture zone, a different capture moiety, each capture moiety capable of capturing a different target; and, separately, a plurality of different detection probes, each detection probe capable of binding to a different target and each detection probe being labelled with or enabling the formation of a detection signal so that the presence of each target is indicated by the formation of a signal at the capture zone for that target; wherein the target for at least two of the capture moieties is an infectious agent or a disease causing micro-organism or a marker indicating the existence of a disease, disorder, or condition of the host from which the sample solution was derived, and wherein at least two of the capture moieties are capable of binding to different components or markers of the same infectious agent or disease causing microorganism, or to different markers

- 3 -

for the same disease, disorder, or condition not caused by an infectious agent or disease causing microorganism, as targets for those capture moieties.

5 The marker may be any marker indicating the existence of any disease, disorder, or condition which it is possible to detect using a dipstick. The marker may, for example, be an antibody raised in the host in response to infection by an infectious agent or disease causing microorganism, or a chemical indicating the existence of a disorder such as a
10 metabolic disorder.

An example of a condition which may be tested for includes HLA subtype. The markers may be markers for pregnancy.

To test for the presence of the plurality of different targets in the sample solution, the plurality of different
15 detection probes may be added to the sample solution and the dipstick immersed in the sample solution so that the capture zones are immersed in the sample solution.

Alternatively, the dipstick may further comprise a contact end, remote from the capture zones, for contacting the
20 sample solution, and be capable of transporting the sample solution by capillary action to the capture zones when the sample solution is contacted with the contact end.

To test for the presence of the plurality of targets in the sample solution, the plurality of detection probes are added
25 to the sample solution to allow binding of the detection probes to target in the sample solution. The contact end of the dipstick is contacted with the sample solution to cause sample solution and target-detection probe complexes to rise up the dipstick by capillary action to the capture zones
30 where they can be detected.

- 4 -

The detection probes may alternatively be releasably immobilised to the dipstick. Thus, according to a second aspect of the invention there is provided a dipstick for testing for the presence of a plurality of different targets
5 in a sample solution which comprises:
a plurality of different capture zones and, immobilised to each capture zone, a different capture moiety, each capture moiety capable of capturing a different target; and
a plurality of different detection probes, releasably
10 immobilised to the dipstick, each detection probe capable of binding to a different target and each detection probe being labelled with or enabling the formation of a detection signal so that the presence of each target is indicated by the formation of a signal at the capture zone for that
15 target; wherein the target for at least two of the capture moieties is an infectious agent or a disease causing micro-organism or a marker indicating the existence of a disease, disorder, or condition of the host from which the sample solution was derived, and wherein at least two of the
20 capture moieties are capable of binding to different components or markers of the same infectious agent or disease causing micro-organism, or to different markers for the same disease, disorder, or condition not caused by an infectious agent or disease causing microorganism, as
25 targets for those capture moieties.

An advantage of capture moieties being releasably immobilised to the dipstick is that all the components required to obtain a result from a dipstick assay can be present on the dipstick with no other reagents or equipment
30 being required.

To test for the presence of the plurality of different targets in the sample solution using a dipstick of the second aspect of the invention, the dipstick may be immersed

- 5 -

in the sample solution so that the detection probes and the capture zones are immersed in the sample solution. Contact of the detection probes with the sample solution causes them to be released from the dipstick so that they can bind to
5 target in the sample solution which can, in turn bind to its capture moiety and thereby allow detection of the target.

Alternatively, a dipstick of the second aspect of the invention may further comprise a contact end, remote from the capture zones, for contacting the sample solution, the
10 detection probes being releasably immobilised between the contact end and the capture zones, wherein the dipstick is capable of transporting the sample solution by capillary action to the capture zones when the sample solution is contacted with the contact end.

15 To test for the presence of the plurality of targets in the sample solution, the contact end of the dipstick may be contacted with the sample solution to cause the sample solution to rise up the dipstick by capillary action to the capture zones. The detection probes are released by the
20 sample solution as it rises up the dipstick allowing them to bind to target in the sample solution. Detection probe-target complexes can then bind capture moiety at the appropriate capture zone.

The marker may be any marker indicating the existence of any
25 disease, disorder, or condition which it is possible to detect using a dipstick. The marker may, for example, be an antibody raised in the host in response to infection by an infectious agent or disease causing microorganism, or a chemical indicating the existence of a disorder such as a
30 metabolic disorder. An example of a condition which may be tested for includes HLA subtype. The markers may be markers for pregnancy.

- 6 -

Dipsticks and kits of the invention, and tests carried out using these have several advantages. The dipsticks and kits allow reliable diagnosis of infection by an infectious agent or disease causing microorganism. Tests using the dipsticks
5 or kits are simple because they can be performed in a very low number of steps, or even a single step. Minimal training is required, therefore, for a person to be able to perform a test. The tests can be performed rapidly. It is possible to carry out a test in less than one hour, including sample
10 preparation time. No specialist equipment is needed. The kits, dipsticks, and any reagents used can be provided at low cost.

Because of these advantages, it will be appreciated that dipsticks and kits of the invention are particularly
15 advantageous for use in performing confirmatory assays for infection by an infectious agent or disease causing microorganism, or for confirming existence of a disease, disorder, or condition not caused by an infectious agent or disease causing microorganism. Such assays can be performed
20 rapidly, thus keeping patient waiting times to a minimum and allowing screening and confirmatory assays to be performed during a single visit from a patient. Such rapid testing can also make it easier to maintain the confidentiality of the patient. The lack of requirement for specialist equipment
25 and the relatively low cost of performing the assays means that tests can be made readily available. This is a particular advantage in resource-poor countries, and in remote areas where the cost of performing conventional tests, and the requirement for specialist equipment to
30 perform the conventional tests can mean that they are not readily available.

The rapidity with which tests using kits and dipsticks of the invention can be performed means that counselling and

- 7 -

treatment can be administered immediately to the patient if a positive result is obtained. This is in contrast to the conventional tests which take much longer to perform. It is often then necessary for a patient to return at a later date
5 which can be several weeks later, and in some cases the patient may never return. Any necessary counselling and treatment would then be significantly delayed or not administered.

Those skilled in the art will appreciate the invention has
10 the advantage that a test or assay can now be designed to take into account any or all known/detectable targets which are available for any specific organism of interest, thereby providing an improved test or assay for that organism.

Detection of different components of the same infectious
15 agent or disease causing microorganism not only allows more reliable diagnosis of an infection, but can also provide information relating to the state of an infection or progression of a disease, disorder or condition.

For example, if a particular antigen is known to occur only
20 during a particular phase of an infection, then knowledge of the presence or absence of this antigen in the patient at the time a sample was taken from the patient could be of assistance in assessing the stage of the infection and, therefore, in determining the most appropriate treatment to
25 be administered.

In some cases, antibodies to both structural and non-structural antigens of an infectious agent or microorganism are seen during an infection and could be used as the basis of an assay of the invention. A serological profile of a
30 patient could be determined which could assist in making

- 8 -

decisions regarding further monitoring or treatment of the infection.

It is desirable in any test or assay to reduce or eliminate false negative results, especially when the test or assay is for detecting an infectious agent or a disease causing microorganism or a marker indicating the existence of a disease, disorder or condition caused by an infectious agent or microorganism. According to the invention it has been appreciated that the same species of microorganism may exhibit different potential "targets" due to there being more than one sub-type, strain, variant, mutant etc of the species. By providing a specific test for multiple targets from the same species the invention can give great specificity to the test yet retain a broad spectrum of applicability, whilst minimising, reducing or eliminating false negative results.

Thus, the invention may also provide a test/assay for distinguishing between or detecting the presence/absence of particular genotypes, serotypes, sub-types, strains, variants, mutants, etc., in a patient sample. This would be of particular value in cases where it is helpful to know whether or not a patient has a particularly virulent or dangerous strain as compared to possibly innocuous or even beneficial/enteric strains.

An example would be to check for E.coli 0157 (a very dangerous, often fatal infectious strain) in the presence of other enteric or infective strains. Another example would be in testing patients for influenza infection, where mutation or variation of the strains is known to occur and some forms of influenza are far more pathogenic than others. A further example is detection of different strains of HIV, for example HIV-1 and HIV-2.

- 9 -

In some embodiments of the invention designed to establish whether a patient is infected with a particular genotype, serotype, sub-type, strain, variant, mutant, etc. (referred to collectively as variants below) of infectious agent or disease causing microorganism, different capture moieties each capable of capturing a target specific to each variant may be immobilised to different capture zones. A capture moiety capable of capturing a target common to all of the variants may also be immobilised at a further capture zone. Thus, identification of which variant is present is confirmed in a single test. The identification of a particular variant could allow the most appropriate treatment for the disease caused by that variant to be administered.

Furthermore, according to the invention it has been appreciated that a single sub-type, strain, mutant, variant etc of a microorganism may exhibit different potential "targets" at different times and/or under different conditions. The present invention provides a kit or dipstick which can be designed to detect such a microorganism regardless of time or condition.

Temporal changes in target may occur for example by virtue of the "life-cycle" of the organism or by virtue of its interaction with a host (ie pre- or post-infection).

Conditional changes in targets may occur for example by virtue of external environmental conditions, conditions in an infected host, sample collection, storage, preparation, handling etc.

The infectious agent or microorganism may be a sexually transmitted disease causing infectious agent or microorganism, such as HIV.

- 10 -

The infectious agent or disease causing microorganism may be any other organism such as Hep B virus, Hep C virus, E.coli, H. Influenzae, Helicobacter.

5 A confirmatory assay for HCV may detect any of core, envelope, NS2, NS3, NS4, and NS5 regions, or antibodies reactive with these regions. For example, purified recombinant antigens or proteins or synthetic peptides representing the core, envelope, NS2, NS3, NS4, or NS5 regions could be immobilised as capture moieties.

10 A confirmatory assay for HIV may detect antibodies to any of the GAG, POL, and ENV regions, for example to p24, p31, gp41, gp120, or gp160. Purified recombinant proteins or synthetic peptides representing these proteins may be immobilised as capture moieties.

15 Antibodies can be used to capture antigens (HbsAg) in the diagnosis of HBV infection.

It is preferred that different targets are detected in a confirmatory assay to those detected in a screening assay so that the possibility of false diagnosis is further
20 minimised. Different detection formats could additionally or alternatively be used to minimise false diagnosis. In particularly preferred embodiments, it is possible to test for different components or markers for infection by HIV and/or HBV and/or HCV on the same dipstick.

25 The signal is preferably a visible signal. This has the significant advantage that additional equipment or reagents are not required to visualise and record the results of tests performed using kits and dipsticks of the invention.

- 11 -

The visible signal used for the detection of each target may be the same colour. However, in some circumstances it is possible that use of the same colour in the detection of each target could allow a positive result for a target to be assigned to the wrong target, particularly to a target which binds to an adjacent capture zone where the capture zones are closely spaced on the dipstick. Any confusion is undesirable as it can lead to mistakes in recording which targets are present or absent in the sample solution. In order to avoid making mistakes in recording which targets are present or absent in a sample solution the position on the dipstick at which a positive result has been obtained could be measured. This may be undesirable as it can slow the speed at which the results can be read from the dipstick. Alternatively, a casing indicating the identity of the target for each capture zone could be provided. However, this may be undesirable as the cost and complexity of the test is increased.

It is an advantage of dipsticks and kits of the invention, that the presence of each target can be indicated by a different colour. Hence, the position at which the result is obtained on the dipstick does not need to be taken into account when interpreting the results. Consequently, results can be recorded more rapidly and the risk of incorrectly recording which targets are present or absent in the sample solution is reduced.

Accordingly, the invention provides a kit or dipstick as described above wherein each detection signal is a different colour.

Each detection probe is preferably directly coupled to a visible label. This allows simple and rapid detection of targets without use of other reagents or equipment.

- 12 -

The detection probes may be nucleic acid or non nucleic acid.

At least one of the detection probes may comprise a nucleic acid or nucleic acid analogue capable of hybridising to its target.

The or each detection probe may comprise a "hook" detection probe capable of binding to the target for that detection probe and a "universal" detection probe capable of binding to the hook detection probe. The hook detection probe and the universal detection probe are preferably nucleic acids or nucleic acid analogues.

At least one of the detection probes may comprise an antibody or an antibody fragment.

At least one of the detection probes may comprise a converting enzyme capable of converting a chromogenic substrate thereby enabling formation of the colour indicating the presence of the target for that detection probe.

A kit of the first aspect of the invention may further comprise the or each chromogenic substrate. A dipstick of the second aspect of the invention may be provided as part of a kit with the or each chromogenic substrate.

If one or more chromogenic substrates are required it will be appreciated that the dipstick will normally be immersed in a separate solution comprising the or each chromogenic substrate after the dipstick has been contacted with the sample solution. In some cases in which more than one chromogenic substrate is required, it may be preferred to have a different solution for each chromogenic substrate and

- 13 -

to sequentially immerse the dipstick in each different solution after it has been contacted with the sample solution. In other arrangements, a solution comprising the or each chromogenic substrate, or different solutions each
5 comprising a different chromogenic substrate, may be applied directly to the appropriate capture zone(s) of the dipstick.

At least one of the detection probes may comprise a detection ligand which can be bound by a colour labelled
10 detection ligand binding moiety thereby enabling formation of the colour indicating the presence of the target for that detection probe.

A kit of the first aspect of the invention may further comprise one or more colour labelled detection ligand binding moieties. A dipstick of the second aspect of the
15 invention may be provided as part of a kit with one or more colour labelled detection ligand binding moieties.

The dipstick of the kit or the dipstick may comprise a contact end and a conjugate zone between the contact end and the capture zones, the or each colour labelled detection
20 ligand binding moiety being releasably immobilised to the conjugate zone.

The detection ligand may be biotin and a colour labelled detection ligand binding moiety may comprise a biotin binding moiety, such as an anti-biotin antibody,
25 streptavidin, avidin or a derivative thereof which retains biotin binding activity.

The detection ligand may be DNP and a colour labelled detection ligand binding moiety may comprise an anti-DNP antibody.

- 14 -

The detection ligand may be FITC and a colour labelled detection ligand binding moiety may comprise an anti-FITC antibody.

5 At least one of the detection probes of kits or dipsticks of the invention may comprise nucleic acid which can be bound by a colour labelled nucleic acid thereby enabling formation of a colour indicating the presence of the target for that detection probe.

10 A kit of the first aspect of the invention may further comprise one or more colour labelled nucleic acid. A dipstick of the second aspect of the invention may be provided as part of a kit with one or more colour labelled nucleic acids.

15 The capture moieties may be nucleic acid or non nucleic acid.

At least one of the capture moieties may comprise a nucleic acid or nucleic acid analogue.

20 A capture moiety comprising a nucleic acid or nucleic acid analogue may be capable of binding directly or indirectly to its target. For example, if the target comprises nucleic acid, the nucleic acid or nucleic acid analogue of the capture moiety may be capable of binding to another nucleic acid or nucleic acid analogue bound to the target.

25 Where the nucleic acid or nucleic acid analogue of the capture moiety is capable of binding to another nucleic acid or nucleic acid analogue bound to the target, it will be appreciated that the latter nucleic acid or nucleic acid analogue should be contacted with, or added to the sample solution in order to detect the presence of the target.

- 15 -

Consequently, a dipstick of the invention may be provided with, or a kit of the invention may include, a nucleic acid or nucleic acid analogue to be contacted with, or added to the sample solution in order for a capture moiety to be able to bind indirectly to its target.

The or each capture moiety may comprise a "hook" capture probe capable of binding to the target for that capture moiety and a "universal" capture probe bound to the hook capture probe. The hook capture probe and the universal capture probe are preferably nucleic acids or nucleic acid analogues.

At least one of the capture moieties may comprise an antibody or antibody fragment.

A capture moiety which comprises an antibody or antibody fragment may be capable of binding directly or indirectly to its target. For example, if the target comprises nucleic acid, the antibody or antibody fragment may be capable of binding to a capture ligand of a capture probe hybridised to the target. The capture probe may comprise a nucleic acid or nucleic acid analogue coupled to a capture ligand.

Where a capture moiety comprises an antibody or antibody fragment capable of binding to a capture ligand of a capture probe, it will be appreciated that the capture probe should be contacted with, or added to the sample solution in order to detect the presence of the target. Consequently, a dipstick of the invention may be provided with, or a kit of the invention may include, a capture probe to be contacted with, or added to the sample solution in order for a capture moiety to be able to bind indirectly to its target.

- 16 -

In some embodiments of the invention, a plurality of different capture probes (which are non nucleic acid or non nucleic acid) may be used to capture a target, each of the different capture probes capable of being bound by a capture moiety. For example, if the target comprises nucleic acid, several different nucleic acid capture probes could be provided, each capable of binding to a different region of the target, but each capture probe comprising a capture ligand which can be bound by the same capture moiety.

Where a target comprises nucleic acid, a capture moiety immobilised at its capture zone may comprise an antibody or antibody fragment bound to the capture ligand of a capture probe capable of hybridising to the nucleic acid of the target.

Examples of suitable capture ligands include biotin, FITC and DNP. These ligands can be bound by anti-biotin, anti-FITC, and anti-DNP antibodies, respectively.

A first capture moiety may be capable of binding to nucleic acid of the infectious agent or disease causing microorganism and a second capture moiety may be capable of binding to an antigen of the same infectious agent or disease causing microorganism.

A first detection probe may be capable of binding to nucleic acid of the infectious agent or disease causing microorganism and a second detection probe may be capable of binding to an antigen of the same infectious agent or disease causing microorganism.

A first detection probe may be capable of binding to a first nucleic acid of the infectious agent or disease causing microorganism and the second detection probe may be capable

- 17 -

of binding to a second nucleic acid of the same infectious agent or disease causing microorganism.

5 A first detection probe may be capable of binding to a first antigen of the infectious agent or disease causing microorganism and a second detection probe may be capable of binding to a second antigen of the same infectious agent or disease causing microorganism.

10 In some embodiments of the invention, a plurality of different detection probes may be used to detect a target, each of the different detection probes capable of being bound by a colour labelled detection ligand binding moiety. For example, if the target comprises nucleic acid, several different detection probes could be provided, each capable of binding to a different region of the target, but each
15 detection probe comprising a detection ligand which can be bound by the same colour labelled detection ligand binding moiety.

In some embodiments of the invention, there may be the same number of capture moieties as detection probes.

20 Where different colours are used preferably there are the same number of capture moieties as detection colours.

There is also provided according to the invention use of a kit or a dipstick of the invention for testing for the presence of a plurality of different targets or markers for
25 the same infectious agent or disease causing microorganism, or markers for the same disease, disorder, or condition not caused by an infectious agent or disease causing microorganism in a sample solution.

- 18 -

Examples of suitable colour labels to be used in kits or dipsticks of the invention include a textile dye, a metal sol such as colloidal gold, and/or coloured particles such as coloured latex particles. Textile dyes are particularly preferred because they are stable, inexpensive, and available in a wide range of colours.

Where the detection signal is not provided by a colour label it may be provided by any suitable signal-producing moiety known to those skilled in the art. Examples are (but are not limited to) radio-labels, fluorescence-labels, stains etc.

The sample solution may be a blood sample, a urine sample or it may be derived from a blood sample, urine sample, swab or other sample (for example a tissue sample) obtained from a host in order to test for the presence of a plurality of targets in the host.

In a further aspect of the invention a plurality of different capture moieties capable of binding to different targets which are components or markers of the same infectious agent or disease causing microorganism, or to different markers for the same disease, disorder or condition not caused by an infectious agent or disease causing microorganism, are immobilised to the same capture zone of a dipstick. A plurality of detection probes are provided either separately from the dipstick or releasably immobilised to the dipstick, each detection probe being capable of binding to a different target and each detection probe being labelled with or enabling the formation of a detection signal so that the presence of each target is indicated by the formation of a signal at the capture zone.

- 19 -

Example

This example shows that different detection probes labelled with different colours can bind specifically to different capture zones of a dipstick and be clearly distinguished on the dipstick. Although the example does not illustrate detection of the presence of different targets from the same microorganism in a sample solution, a person of ordinary skill in the art will readily appreciate how this may be achieved from its teaching. As noted above, the present invention is not limited solely to the use of coloured signals.

Method:Dye Washing

0.6 g of navy and pink textile dyes were resuspended in 12 ml of a buffer comprising:
10 mM Sodium Phosphate pH 7.5, 10 mM Sodium Chloride and 1 mM EDTA.**

The dyes were washed by centrifugation followed by resuspension in the above buffer (x3).

Attachment/ conjugation to antibody

The dyes were diluted to an O.D. reading of:

- A = 50 at 570 nm for the navy dye .
- A = 25 at 35 nm for the pink dye.

The navy dye was conjugated to an anti-FITC antibody by combining:

500 ul of the navy dye, 3.468 ul of the buffer **, and 25 ug of anti-FITC antibody.

The solution was mixed for 1 hour after which 500 ul of 20 % (w/v) blocking agent, such as BSA, was added.

- 20 -

The conjugate was stirred for a further hour after which 500 ul of 50 % (w/v) sucrose and Proclin (preservative) was added.

5 The pink dye was conjugated to an anti-biotin antibody using the method outlined above, the only difference being the initial concentration of the dye (A=25) and the antibody(anti-biotin).

Test system:

10 BSA, BSA conjugated to FITC and BSA conjugated to biotin were applied to different zones of a nitro-cellulose dipstick at 1.5, 1.3 and 1 cm from the bottom of the dipstick, respectively.

The following reagents were combined for the different test runs:

15 100 ul of a buffer comprising 50 mM Sodium phosphate pH 7.5, 1 % PEG, 1 % Triton X-305, 1 mM EDTA, 0.02 % Gelatin & 0.02 % Ficoll 400 and:

Run1:

20 50 ul of 10 mM Sodium Phosphate, 10 mM Sodium Chloride, 1 mM EDTA + 50 ul of navy dye anti-FITC conjugate

Run2:

50 ul of 10 mM Sodium Phosphate, 10 mM Sodium Chloride, 1 mM EDTA + 50 ul of pink dye anti-Biotin conjugate

Run 3:

25 50 ul of navy dye anti-FITC conjugate + 50 ul of pink dye anti-biotin conjugate.

- 21 -

Results:

As illustrated schematically in Figure 1, specific capture of the dye conjugates occurred at each capture zone whether tested singly or in combination, i.e. no visual readout at
5 the BSA capture zone 1.5 cm from the base of the membrane and specific signal generation at the BSA-FITC and/or BSA-biotin capture zones. No false positives or change in the colour of the visual readout was observed.

The experiment was repeated using dye conjugates which were
10 dried onto a conjugate pad and released by the migration of sample buffer. The same specific result was obtained.

- 22 -

Claims

1. A kit for testing for the presence of a plurality of different targets in a sample solution which comprises:
a dipstick having a plurality of different capture zones
5 and, immobilised to each capture zone, a different capture moiety, each capture moiety capable of capturing a different target; and, separately,
a plurality of different detection probes, each detection probe capable of binding to a different target and each
10 detection probe being labelled with or enabling the formation of a detection signal so that the presence of each target is indicated by the formation of a signal at the capture zone for that target; wherein the target for at least two of the capture moieties is an infectious agent or
15 a disease causing micro-organism or a marker indicating the existence of a disease, disorder, or condition of the host from which the sample solution was derived, and wherein at least two of the capture moieties are capable of binding to different components or markers of the same infectious agent
20 or disease causing micro-organism, or to different markers for the same disease, disorder or condition not caused by an infectious agent or disease causing microorganism, as targets for those capture moieties.
2. A kit according to claim 1 in which the dipstick
25 comprises a contact end, remote from the capture zones, for contacting the sample solution, the dipstick being capable of transporting the sample solution by capillary action to the capture zones when the sample solution is contacted with the contact end.
- 30 3. A dipstick for testing for the presence of a plurality of different targets in a sample solution which comprises:

- 23 -

a plurality of different capture zones and, immobilised to each capture zone, a different capture moiety, each capture moiety capable of binding to a different target; and a plurality of different detection probes, releasably
5 immobilised to the dipstick, each detection probe capable of binding to a different target and each detection probe being labelled with or enabling the formation of a detection signal so that detection of each target is indicated by the formation of a signal at the capture zone for that target;
10 wherein the target for at least two of the capture moieties is an infectious agent or a disease causing micro-organism or a marker indicating the existence of a disease, disorder, or condition of the host from which the sample solution was derived, and wherein at least two of the capture moieties
15 are capable of binding to different components or markers of the same infectious agent or disease causing micro-organism, or to different markers for the same disease, disorder or condition not caused by an infectious agent or disease causing microorganism, as targets for those capture
20 moieties.

4. A dipstick according to claim 3 which comprises a contact end, remote from the capture zones, for contacting the sample solution, and in which the detection probes are releasably immobilised between the contact end and the
25 capture zones, wherein the dipstick is capable of transporting the sample solution by capillary action to the capture zones when the sample solution is contacted with the contact end.

5. A kit or dipstick according to any of claims 1 to 4
30 wherein each detection signal is a different colour.

6. A kit or a dipstick according to any preceding claim in which at least one of the detection probes comprises a

- 24 -

nucleic acid or nucleic acid analogue capable of hybridising to its target.

7. A kit or a dipstick according to any preceding claim in which at least one of the detection probes comprises an antibody or an antibody fragment.

8. A kit or a dipstick according to any preceding claim in which at least one of the detection probes is labelled with a textile dye, a metal sol such as colloidal gold, or coloured particles such as coloured latex particles.

9. A kit or a dipstick according to any preceding claim in which at least one of the detection probes comprises a converting enzyme capable of converting a chromogenic substrate thereby enabling formation of a colour signal indicating the presence of the target for that detection probe.

10. A kit according to claim 9 which further comprises the or each chromogenic substrate, or a kit comprising a dipstick according to claim 9 and the or each chromogenic substrate.

11. A kit or a dipstick according to any preceding claim in which at least one of the detection probes comprises a detection ligand which can be bound by a colour labelled detection ligand binding moiety thereby enabling formation of a colour indicating the presence of the target for that detection probe.

12. A kit according to claim 11 which further comprises the or each colour labelled detection ligand binding moiety, or a kit comprising a dipstick according to claim 11 and the or each colour labelled detection ligand binding moiety.

- 25 -

13. A kit or a dipstick according to claim 11 in which the dipstick of the kit or the dipstick comprises a contact end and a conjugate zone between the contact end and the capture zones, the or each colour labelled detection ligand binding moiety being releasably immobilised to the conjugate zone.

14. A kit according to any of claims 11 to 13 in which the, or at least one of the, detection ligand is biotin and the, or at least one of the, colour labelled detection ligand binding moieties comprises an anti-biotin antibody.

15. A kit according to any of claims 11 to 14 in which the, or at least one of the, detection ligands is FITC or DNP and the, or at least one of the, colour labelled detection ligand binding moieties comprises an anti-FITC antibody or an anti-DNP antibody, respectively.

16. A kit or a dipstick according to any preceding claim in which at least one of the detection probes comprises nucleic acid which can be bound by a colour labelled nucleic acid thereby enabling formation of the colour indicating the presence of the target for that detection probe.

17. A kit according to claim 16 which further comprises the or each colour labelled nucleic acid, or a kit comprising a dipstick according to claim 16 and the or each colour labelled nucleic acid.

18. A kit or a dipstick according to any preceding claim in which at least one of the capture moieties comprises a nucleic acid or nucleic acid analogue.

19. A kit or a dipstick according to any preceding claim in which at least one of the capture moieties comprises an antibody or antibody fragment.

- 26 -

20. A kit or a dipstick according to any preceding claim in which a first capture moiety is capable of binding to nucleic acid of the disease causing microorganism and a second capture moiety is capable of binding to an antigen of the same disease causing microorganism.

21. A kit or a dipstick according to any preceding claim in which at least two of the detection probes are capable of binding to different components of the same disease causing micro-organism as targets for those detection probes.

22. A kit or a dipstick according to claim 21 in which a first detection probe is capable of binding to nucleic acid of the disease causing microorganism and a second detection probe is capable of binding to an antigen of the same disease causing microorganism.

23. A kit or a dipstick according to any preceding claim in which the infectious agent or disease causing micro-organism is a sexually transmitted disease causing microorganism, such as HIV.

24. A kit or dipstick according to any preceding claim in which the infectious agent or disease causing microorganism is Hep A virus, Hep B virus, Hep C Virus, E.Coli, H. Influenzae, or Helicobacter.

25. A kit or dipstick according to any preceding claim in which the different components or markers are specific for different genotypes, serotypes, sub-types, variants, strains, or mutants of the disease, disorder, or condition.

26. A kit or dipstick according to any preceding claim in which the different components or markers are produced and/or are available at different times and/or under

- 27 -

different conditions during the course of the disease, disorder, or condition.

27. A kit or a dipstick according to any preceding claim in which there are the same number of capture moieties as
5 detection signals, for example colour signals.

28. Use of a kit or a dipstick according to any preceding claim for testing for the presence of a plurality of different targets in a sample solution.

29. An assay for testing for the presence of a plurality of
10 different targets in a sample solution which comprises:
providing a dipstick having a plurality of different capture zones and, immobilised to each capture zone, a different capture moiety, each capture moiety capable of capturing a different target;
15 contacting the sample solution with a plurality of different detection probes, each detection probe capable of binding to a different target and each detection probe being labelled with or enabling the formation of a different detection signal; and
20 contacting the sample solution with the dipstick so that targets in the sample solution can bind to the capture moieties at the capture zones and so that the presence of each target is indicated by the formation of a signal at the capture zone for that target, wherein the target for at
25 least two of the capture moieties is an infectious agent or a disease causing micro-organism, or a marker indicating the existence of a disease, disorder, or condition of the host from which the sample solution was derived, and wherein at
least two of the capture moieties are capable of binding to
30 different components or markers of the same infectious agent or disease causing micro-organism, or to different markers for the same disease, disorder or condition not caused by an

- 28 -

infectious agent or disease causing microorganism, as targets for those capture moieties.

30. An assay according to claim 29 in which the detection probes, instead of being contacted with the sample solution,
5 are contacted with the dipstick after the targets have been captured at the capture zones.




Figure 1

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 01/04589

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/558 G01N33/569 G01N33/571

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 770 460 A (PRONOVOST ALLAN D ET AL) 23 June 1998 (1998-06-23) the whole document ----	1-30
X	WO 98 36278 A (BETH ISRAEL HOSPITAL) 20 August 1998 (1998-08-20) abstract; figure 1 ----	1-30
X	WO 94 23299 A (QUIDEL CORP) 13 October 1994 (1994-10-13) the whole document ----	1-30
X	WO 94 29696 A (QUIDEL CORP) 22 December 1994 (1994-12-22) abstract; figure 1 ----- -/--	1-30

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

7 January 2002

Date of mailing of the international search report

15/01/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Moreno, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 01/04589

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 27081 A (DU PONT) 12 October 1995 (1995-10-12) abstract; figure 1 ----	1-30
A	WO 96 19731 A (ABBOTT LAB) 27 June 1996 (1996-06-27) abstract ----	1, 3, 29
A	US 5 741 662 A (BAUTISTA LORRAINE S ET AL) 21 April 1998 (1998-04-21) abstract ----	1, 3, 29
A	US 5 141 850 A (MACDONNELL PAUL C ET AL) 25 August 1992 (1992-08-25) abstract -----	1, 3, 29

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 01/04589

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5770460	A	23-06-1998	US 5766961 A	16-06-1998
			DE 69229334 D1	08-07-1999
			DE 69229334 T2	16-12-1999
			EP 0566695 A1	27-10-1993
			JP 2868900 B2	10-03-1999
			JP 6504846 T	02-06-1994
			WO 9212428 A1	23-07-1992
WO 9836278	A	20-08-1998	AU 6277498 A	08-09-1998
			WO 9836278 A1	20-08-1998
WO 9423299	A	13-10-1994	WO 9423299 A1	13-10-1994
WO 9429696	A	22-12-1994	EP 0705426 A1	10-04-1996
			JP 8511621 T	03-12-1996
			WO 9429696 A1	22-12-1994
WO 9527081	A	12-10-1995	WO 9527081 A1	12-10-1995
			US 6037127 A	14-03-2000
WO 9619731	A	27-06-1996	CA 2207759 A1	27-06-1996
			EP 0799421 A2	08-10-1997
			JP 10511460 T	04-11-1998
			WO 9619731 A2	27-06-1996
US 5741662	A	21-04-1998	WO 9722714 A1	26-06-1997
US 5141850	A	25-08-1992	AT 161965 T	15-01-1998
			AU 644423 B2	09-12-1993
			AU 7445891 A	03-09-1991
			CA 2073504 A1	08-08-1991
			DE 69128618 D1	12-02-1998
			DE 69128618 T2	07-05-1998
			DK 514489 T3	06-04-1998
			EP 0514489 A1	25-11-1992
			ES 2110990 T3	01-03-1998
			GR 3025848 T3	30-04-1998
			JP 2532788 B2	11-09-1996
			WO 9112528 A1	22-08-1991